• +613 8892 4854
  • info@immuron.com

    :

Immuron
  • +613 8892 4854
  • info@immuron.com
  • Cart - 0

  • Menu

  • Shop

  • Cart (0)

  • Account
  • About Us
    • About Us
    • Board of Directors
    • Management Team
    • Research Partners
  • Technology
    • Technology Platform
    • Product Pipeline
    • Intellectual Property
    • Production
  • Clinical Insights
    • Commercial products
    • In vitro studies into SARS-CoV-2 and IMM-124E
    • Travelan US Army results
  • Knowledge Centre
    • Platform Science
    • Product Science
  • Investor Centre
    • Company Media
    • Analysts Reports
    • Corporate Presentations
    • Company Securities Exchange Announcements
    • Capital Structure & Register
    • Corporate Directory and Governance
    • Corporate Contacts
  • Contact Us
  • Products
    • Travelan®
    • Protectyn®
  • About Us
    • About Us
    • Board of Directors
    • Management Team
    • Research Partners
  • Technology
    • Technology Platform
    • Product Pipeline
    • Intellectual Property
    • Production
  • Clinical Insights
    • Commercial products
    • In vitro studies into SARS-CoV-2 and IMM-124E
    • Travelan US Army results
  • Knowledge Centre
    • Platform Science
    • Product Science
  • Investor Centre
    • Company Media
    • Analysts Reports
    • Corporate Presentations
    • Company Securities Exchange Announcements
    • Capital Structure & Register
    • Corporate Directory and Governance
    • Corporate Contacts
  • Contact Us
  • Travelan®
  • Protectyn®

Categories

  • Products

Information

  • About Us
  • Returns Policy
  • Contact Us
  • Travelan®
  • Protectyn®
  • Home
  • Investor Centre
  • Company Securities Exchange Announcements

Company Securities Exchange Announcements

2022 ASX Announcements

US DoD NMRC files IND application with FDA (11/05/2022)

US DoD Uniformed Services University Clinical Update (09/05/2022)

Appointment of Mr Steven Lydeamore as Chief Executive Officer (05/05/2022)

Immuron Q3 Global Sales up 216% YoY (27/04/22)

Immuron new MTEC project proposal (19/04/22)

Half Yearly Report and Accounts (25/02/22)

Response to ASX query (24/01/22)

Changes in substantial holding (24/01/22)

Immuron receives $306,154 R&D Tax Concession Refund (17/01/22)

Immuron receives European patent on Drug to treat Diarrhoea (13/01/22)

Change in substantial holding (13/01/22)

Immuron awarded $6.2 million US DoD funding for Travelan (12/01/22)

Change in substantial holding (6/01/22)

2021 and 2020 ASX Announcements

View 2021 and 2020 ASX announcements

To view Immuron ASX Market Announcements for all years prior to 2020, please click here and enter Immuron's company code IMC.

 

Partners

Feature Products 8
Footer Logo 8
Footer 9
Footer Logo 1
Footer Logo 2
Footer Logo 3
Footer Logo 4
Footer Logo 6

Secure Shopping

Fully protected by Incapsula

 

Get Connected

Join our social networks

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.

The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.

Copyright © 2022 Immuron

E-commerce software by Neto

About Us

  • About Us
  • Travelan
  • Protectyn
  • Clinical Insights
  • Contact Us

Information

  • Terms of Use
  • Privacy Policy
  • Returns Policy
  • Security Policy

Payment Options

Contact Information

  • Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
  • Phone: +613 8892 4854
  • Fax: +613 9899 8533